Orphalan S.a.

Naseem Amin

Ronnie Maxwell Lawrence

Timothy James Morley

The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1° 2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use

The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3&#xb1;0.1&#xb0;2&#x3b8; and Raman shifts 943, 1173, 1527 and 1612&#xb1;5 cm. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

Growing community of inventors

London, United Kingdom

Naseem Amin